category:news
Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm
Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
company:novo-nordisk
Novo Nordisk offers cheaper Wegovy
Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
category:news
VK2735's manufacturing alliance with CordenPharma
Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735
category:news
BRP - a new GLP1-like peptide
We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.
company:hims
HIMS ends compounded Semaglutide offering
Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
chemical:semaglutide
Semaglutide removed from shortage list
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
country:mexico
Mexico and GLP1s
We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.
category:watercooler
Shortages threaten corporate profits, likely to end soon
We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news
Ozempic approved for Chronic Kidney Disease
The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
Tradjenta: An alternative to GLP1 for Type 2 Diabetes
We take a look at one of the alternatives to GLP1s that has been on the market a long time -- Tradjenta.
category:watercooler
GLP1 use by younger people
We dig into the reports of younger people using GLP1s like Ozempic, Wegovy and others.
company:novo-nordisk
Novo's Amycretin delivers great Phase 2 results
Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.